Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from botswana

Clinical Infectious Diseases

Volumn 48, Issue 12, 2009, Pages 1685-1694

  Chideya, Sekai ^a,g   Winston, Carla A ^a   Peloquin, Charles A ^b   Bradford, William Z ^c,d   Hopewell, Philip C ^c   Wells, Charles D ^a   Reingold, Arthur L ^d   Kenyon, Thomas A ^a,e   Moeti, Themba L ^f   Tappero, Jordan W ^a,e  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Botswana/USA Tuberculosis Project   (Botswana)

^f Department of HIV AIDS Prevention and Care   (Botswana)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BOTSWANA; CD4 LYMPHOCYTE COUNT; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 66949172863     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/599040     Document Type: Article

References (34)

1. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163:1009-21.
2. World Health Organization. TB/HIV. Available at: http://www.who.int/ tb/hiv/faq/en/index.html. Accessed 15 June 2007.
3. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3:S231-79.
4. Iseman MD. Tuberculosis therapy: past, present and future. Eur Respir J Suppl 2002; 20:87s-94s.
5. Holdiness M. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 1984;9:511-44.
6. Pillai G, Fourie PB, Padayatchi N, et al. Recent bioequivalence studies on fixed-dose combination antituberculosis drug formulations available on the global market. Int J Tuberc Lung Dis 1999;3(Suppl 3): S309-16.
7. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. Determinants of rifampin, isoniazid, pyrazinamide and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006;50:1170-7.
8. Wilkins JJ, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson USH. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur J Clin Pharmacol 2006; 62: 727-35.
9. Patel KB, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV-infected patients. N Engl J Med 1995;332:336-7.
10. Peloquin CA, Nitta AT, Burman WJ, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996;30:919-25.
11. Sahai J, Gallicano K, Swick L, et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 1997; 127:289-93.
12. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al. Mal- absorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin Infect Dis 2004; 38:280-3.
13. Harries AD, Hargreaves NJ, Salaniponi FM. Design of regimens for treating tuberculosis patients with HIV infection, with particular reference to sub-Saharan Africa. Int J Tuberc Lung Dis 2001;5:1109-15.
14. World Health Organization. TB/HIV: a clinical manual. 2nd ed. Geneva, Switzerland: World Health Organization, 2004.
15. Chaisson RE, Clermont HC, Holt EA, et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996; 154:1034-8.
16. Weiner M, Burman W, Vernon A, et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 2003; 167:1341-7.
17. Weiner M, Benator D, Burman W, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005; 40:1481-91.
18. Mehta JB, Shantaveerapa H, Byrd RP, et al. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest 2001; 120:1520-4.
19. Nelson LJ, Talbot EA, Mwasekaga MJ, et al. Anti-tuberculosis drug resistance and anonymous HIV surveillance among tuberculosis patients-Botswana. Lancet 2005; 366:488-90.
20. Talbot EA, Burgess DCH, Hone NM, et al. Tuberculosis serodiagnosis in a predominantly HIV-infected population of hospitalized patients with cough, Botswana 2002. Clin Infect Dis 2004; 39:e1-7.
21. World Health Organization. TB country profiles. Available at: http://www.who int/globalatlas/predefinedreports/tb/PDF-Files/bwa.pdf. Accessed 23 May 2007.
22. Tappero JW, Bradford WZ, Agerton TB, et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis 2005;41:461-9.
23. Botswana National Tuberculosis Programmme. Botswana National Tuberculosis Guidelines. 5th ed. Botswana: Botswana National Tuberculosis Programmme, 1995.
24. Peloquin CA. Antituberculosis drugs: pharmacokinetics. In: Heifets L, ed. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press, 1991:59-88.
25. Peloquin CA, Bulpitt AE, Jaresko GS, et al. Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. Pharmacotherapy 1998; 18:1205-11.
26. Peloquin CA, Bulpitt AE, Jaresko GS, et al. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother 1999; 43:568-72.
27. Peloquin CA, Namdar R, Dodge RR, Nix DE. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. Int J Tuberc Lung Dis 1999; 3:703-10.
28. Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 1999; 115:12-8.
29. Zhang Y, Mitchison DA. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003; 7:6-21.
30. Mitchison DA. The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med 2005; 171:699-706.
31. Peloquin CA, Jaresko GS, Yong CL, Keung AC, Bulpitt AE, Jelliffe RW. Population pharmacokinetic modeling of isoniazid, rifampin, and pyr- azinamide. Antimicrob Agents Chemother 1997;41:2670-9.
32. Grosset J. The sterilizing value of rifampin and pyrazinamide in experimental short-course chemotherapy. Bull Int Union Tuberc 1978;53:5-12.
33. World Health Organization. Global tuberculosis control: surveillance, planning, and financing. Geneva, Switzerland: World Health Organization, 2005.
34. Johnson JL, Okwera A, Vjecha MJ, et al. Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis. Int J Tuberc Lung Dis 1997; 1:446-53.